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Abstract
Introduction: There is renewed interest in blood product use for resuscitation stimulated by recent military
experience and growing recognition of the limitations of large-volume crystalloid resuscitation.
Methods: An editorial review of recent reports published by investigators from the United States and Europe is
presented. There is little prospective data in this area.
Results: Despite increasing sophistication of trauma care systems, hemorrhage remains the major cause of early
death after injury. In patients receiving massive transfusion, defined as 10 or more units of packed red blood cells
in the first 24 hours after injury, administration of plasma and platelets in a ratio equivalent to packed red blood
cells is becoming more common. There is a clear possibility of time dependent enrollment bias. The early use of
multiple types of blood products is stimulated by the recognition of coagulopathy after reinjury which may occur
as many as 25% of patients. These patients typically have large-volume tissue injury and are acidotic. Despite early
enthusiasm, the value of administration of recombinant factor VIIa is now in question. Another dilemma is
monitoring of appropriate component administration to control coagulopathy.
Conclusion: In patients requiring large volumes of blood products or displaying coagulopathy after injury, it
appears that early and aggressive administration of blood component therapy may actually reduce the aggregate
amount of blood required. If recombinant factor VIIa is given, it should be utilized in the fully resuscitated patient.
Thrombelastography is seeing increased application for real-time assessment of coagulation changes after injury
and directed replacement of components of the clotting mechanism.
Pathogenesis of Acute Coagulopathy After
Trauma
Historical Perspective
Hemorrhagic shock accounts for a significant number of
deaths in patients arriving at hospital with acute injury
[1,2]. Patients with uncontrolled hemorrhage continue
to succumb despite adoption of damage control techni-
ques and improved transport and emergency care. Coa-
gulopathy, occurring even before resuscitation,
contributes significantly to the morbidity associated with
bleeding [3,4]. Recognition of the morbidity associated
with bleeding and coagulation abnormality goes back to
the work of Simmons and coworkers during the Viet-
nam conflict [5]. Even at that time, standard tests
including prothrombin time (PT) and partial thrombo-
plastin time (PTT) correlated poorly with acute
resuscitation efforts. Similar work in the late 1970s was
performed in civilian patients receiving massive transfu-
sion. Again, PT, PTT and bleeding time were only help-
ful if markedly prolonged [6].
Lucas and Ledgerwood performed a variety of studies
in large animals and patients to determine changes in
the coagulation profile with hemorrhagic shock [7]. In
patient studies, platelet count fell until 48 hours after
injury and increased dramatically during convalescence.
Bleeding times and platelet aggregation studies mirrored
platelet levels. Reductions in fibrinogen, Factor V and
Factor VIII were noted with hemorrhagic shock which
normalized by day one after bleeding. By day four after
bleeding, fibrinogen increased to supranormal levels.
Clotting times mirrored fibrinogen, Factor V and Factor
VIII levels. These investigators then studied the role of
Fresh Frozen Plasma (FFP) supplementation in hemor-
rhagic shock with two studies. In animal studies, sub-
jects received shed blood and crystalloid with some
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work, Fresh Frozen Plasma did not improve coagulation
factors, fibrinogen and Factors II, V, VII and VIII. In a
second controlled study, fresh frozen plasma was given
not only during blood volume restoration but also for
an additional hour during ongoing controlled hemor-
rhage without shock. Fresh Frozen Plasma prevented
reduction in coagulation factors compared to animals
not receiving fresh frozen plasma. Clotting times paral-
leled coagulation factor levels. From this work, Lucas
and Ledgerwood ultimately concluded that hemorrhagic
shock resuscitation requires restoration of blood loss
with packed cells and crystalloid while FFP is appropri-
ately added due to losses of coagulation proteins [7].
Studies in the 1970s and 1980s provided additional
detail regarding the limitation of simple laboratory para-
meters and factor levels in evaluation of patient
response to massive transfusion [6,8]. In a study of 27
patients requiring massive transfusion, platelet counts
fell in proportion to the size of transfusion while Factors
V and VIII correlated poorly with the volume of blood
transfused. Where coagulopathy appeared, the majority
of patients responded to platelet administration. In this
early work, the most useful laboratory test for predicting
abnormal bleeding was the platelet count. A falling fibri-
nogen level was felt to be indicative of DIC. The bleed-
ing time, prothrombin time and partial thromboplastin
time were not helpful in assessing the cause of bleeding
unless they were greater than 1.5 times the control
value [6]. In a subsequent series of studies from the
same investigative group, 36 massively transfused
patients were followed for microvascular bleeding. Mod-
erate deficiencies in the clotting factors evaluated were
common but they were not associated with microvascu-
lar bleeding. Microvascular bleeding was associated with
severe coagulation abnormalities such as clotting factor
levels less than 20% of control. In statistical analysis,
clotting factor activities less than 20% of control were
reliably reflected by significant prolongation of PT and
PTT. These investigators also suggested that empiric
blood replacement formulas available at the time were
not likely to prevent microvascular bleeding because
consumption of platelets or clotting factors did not con-
sistently appear and simple dilution frequently did not
correspond to microvascular bleeding [8].
The attention of the American trauma community was
drawn to coagulopathy after trauma with description of
the “bloody vicious cycle” by the Denver Health team
over 20 years ago [3]. These investigators noted the con-
tribution of hypothermia, acidosis and hemodilution
associated with inadequate resuscitation and excessive
use of crystalloid. Subsequent work extended these
observations describing early coagulopathy which could
be independent of clotting factor deficiency (consistent
with scattered earlier observations) [9]. Moore and
others, in a recent multicenter trial of hemoglobin oxy-
gen carriers, observed early coagulopathy in the setting
of severe injury, which was present in the field, prior to
Emergency Department arrival and initiation of resusci-
tation. Coagulopathic patients were at increased risk for
organ failure and mortality. One concern in the presen-
tation of these patients was inconsistency in available
laboratory data which identified patients at risk [10].
Dating to development of Advanced Trauma Life Sup-
port, trauma teams have used fixed guidelines for
plasma and platelet replacement during massive transfu-
sion to prevent and correct dilutional coagulopathy.
Empiric plasma and platelet replacement was based on
washout physiology, a mathematical model of exchange
transfusion. The model assumes stable blood volume
and calculates exponential decay of each blood compo-
nent with bleeding. In severe injury, however, these
assumptions may not apply: blood volume fluctuates
widely and bleeding rates vary with blood pressure and
replacement frequently lags behind blood loss. Replace-
ment guidelines based on simple washout physiology
may be inadequate [11-14].
In one of the first papers to question historical trans-
fusion practice in the setting of massive trauma, Hirsh-
berg, Mattox and coworkers, utilizing clinical data,
developed a computer model designed to capture inter-
actions between bleeding, hemodynamics, hemodilution
and blood component replacement during severe
hemorrhage. Replacement options were offered in the
model and their effectiveness evaluated [11].
In the computer model, an intravascular compartment
was created accepting crystalloid infusion and calculat-
ing the exchange of free water between intravascular
and interstitial spaces. The basic compartment model
was a “leaky bucket” where inflow is determined by a
clinical scenario and outflow (bleeding rate) is propor-
tional to systolic blood pressure. The effectiveness of
crystalloid resuscitation decreases during massive
hemorrhage in proportion to the volume of blood lost.
In this computer simulation, an exponential model of
effectiveness for crystalloid resuscitation is employed.
Hemostasis was modeled by a relationship sensitive to
blood pressure with 90 mmHg associated with ongoing
bleeding and 50 mmHg associated with minimal blood
loss. The impact of dilution on prothrombin time, fibri-
nogen and platelets were based on data obtained from
dilution curves in the hospital coagulation laboratory
from patients with significant hemorrhage. Standard
product replacement quantities were assumed [11,15,16].
After setting thresholds for acceptable loss of clotting
factors, platelets and fibrinogen, the authors modeled
behavior of coagulation during rapid exsanguination
without clotting factor or platelet replacement. The
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fibrinogen and platelets. If patients were resuscitated with
smaller amounts of crystalloid, leaving overall blood
volume reduced, the effective life of components of the
coagulation cascade was increased. More aggressive Fresh
Frozen Plasma (FFP) replacement was indicated by this
model. The optimal ratio for administration of FFP to
packed red blood cells (PRBCs) in this analysis was 2:3.
Delayed administration of FFP led to critical clotting factor
deficiency regardless of subsequent administration of FFP.
Fibrinogen depletion was easier to correct. Even after
administration of 5 units of PRBCs, the hemostatic thresh-
old for fibrinogen was not exceeded if a FFP to PRBC ratio
of 4:5 was employed. Analysis of platelet dilution show
that even if platelet replacement was delayed until 10 units
of PRBCs were infused, critical platelet dilution was pre-
vented with a subsequent platelet to PRBC ratio of 8:10
[11] (Figure 1).
The essential message of this work is that massive
transfusion protocols in existence when this study was
performed provide inadequate clotting factor replace-
ment during exsanguinating hemorrhage and neither
prevent or correct dilutional coagulopathy.
Acute Coagulopathy of Trauma
Brohi and coworkers from the United Kingdom helped
to reinvigorate discussion of scattered seminal
observations regarding coagulopathy after injury by
adding new coagulation laboratory techniques to earlier
clinical observations [17]. Reviewing over 1,000 cases,
patients with acute coagulopathy had higher mortality
throughout the spectrum of Injury Severity Scores (ISS).
Contrary to historic teaching that coagulopathy was a
function of hemodilution with massive crystalloid
resuscitation, these authors noted that the incidence of
coagulopathy increased with severity of injury but not
necessarily in relationship to the volume of intravenous
fluid administered to patients. Brohi and others helped
to reemphasize the observation that acute coagulopathy
could occur before significant fluid administration which
was attributable to the injury itself and proportional to
the volume of injured tissue. Development of coagulopa-
thy was an independent predictor of poor outcome.
Mediators associated with tissue trauma including
humoral and cellular immune system activation with
coagulation, fibrinolysis, complement and kallikrein cas-
cades have since been associated with changes in hemo-
static mechanisms in the body similar to those identified
in the setting of sepsis [17-19,1].
MacLeod, in a recent commentary, discussed factors
contributing to coagulopathy in the setting of trauma
[20]. That hypothermia relates to development of coagu-
lopathy has been demonstrated in vitro and in clinical
studies. Temperature reduction impairs platelet aggrega-
tion and decreases function of coagulation factors in
non-diluted blood. Patients with temperature reduction
below 34°C had elevated prothrombin and partial
thromboplastin times. Coagulation, like most biological
enzyme systems, works best at normal temperature.
Similarly, acidosis occurring in the setting of trauma as
a result of bleeding and hypotension also contributes to
clotting failure. Animal work shows that a pH <7.20 is
associated with hemostatic impairment. Platelet dysfunc-
tion and coagulation enzyme system changes are noted
when blood from healthy volunteers is subjected to an
acidic environment [21,22].
We are now noting that with or without hypothermia
and acidosis post-traumatic coagulopathy may develop
in a significant number of patients. Possible explanations
for this phenomenon include factor dilution, clotting
system depletion and disseminated intravascular coagu-
lation. Interplay of these and other factors in the face of
ongoing blood loss is still not understood. Crystalloids
and colloids can dilute available clotting factors. Increas-
ing microvascular tissue injury may deplete the coagula-
tion system due to demands of hemorrhage control at
multiple sites. Third, and most interesting, loss of clot-
ting factors associated with exaggerated inflammation is
now being reported in association with injury. The pre-
sence of predictors of coagulopathy has been suggested
by historical data from the United States and the
Figure 1 Behavior of the computer model for massive bleeding
without replacement of clotting factors or platelets. Bleeding
fraction is the volume of blood lost divided by the estimated blood
volume (4,900 mL). Early loss of clotting factors is seen. (Dotted line
is threshold for critical component deficit.)
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epidemiologic data, it is now clear that coagulation
changes after injury reflect more than the amount of
crystalloid given [21-24].
Hess and coworkers as part of an international medi-
cal collaboration (The Educational Initiative on Critical
Bleeding in Trauma) developed a literature review to
increase awareness of coagulopathy independent of crys-
talloid administration following trauma [19]. The key
initiating factor is tissue injury. This is borne out by ori-
ginal work demonstrating the close association between
tissue injury and the degree of coagulopathy. Patients
with severe tissue injury but no physiologic derange-
ment, however, rarely present with coagulopathy and
have a lower mortality rate [25,26]. Tissue damage initi-
ates coagulation as endothelial injury at the site of
trauma leads to exposure of subendothelial collagen and
Tissue Factor which bind von Willebrand factor, plate-
lets and activated Factor VII (FVII). Tissue Factor or
FVII activate plasma coagulation and thrombin and
fibrin are formed. A subsequent amplification process
mediated by factor IX may take place on the surface of
activated platelets [27].
Hyperfibrinolysis is seen as a direct consequence of
the combination of tissue injury and shock. Endothelial
injury accelerates fibrinolysis because of direct release of
Tissue Plasminogen Activator [19,28]. Tissue Plasmino-
gen Activator expression by endothelium is increased in
the presence of thrombin. Fibrinolysis is accelerated
because of the combined affects of endothelial Tissue
Plasminogen Activator release due to ischemia and inhi-
bition of Plasminogen Activator Inhibitor in shock.
While hyperfibrinolysis may focus clot propagation on
the sites of actual vascular injury, with widespread
insults, this localization may be lost. Specific organ inju-
ries have been associated with coagulopathy. Traumatic
brain injury has been noted with increased bleeding
thought due to release of brain-specific thromboplastins
with subsequent inappropriate clotting factor consump-
tion. Hyperfibrinolysis has also been seen in more recent
studies of head-injured patients. Long bone fractures
along with brain and massive soft tissue injury also may
prime the patient for coagulopathy [29,30]. These con-
tributing factors, however, are inadequate to lead to cat-
astrophic coagulopathy if present in isolation.
A number of important cofactors must be present to
stimulate coagulopathy in the setting of trauma [19].
Shock is a dose-dependent cause of tissue hypoperfu-
sion. Elevated base deficit has been associated with
coagulopathy in as many as 25% of patients in one large
study. Progression of shock appears to result in hyperfi-
brinolysis. The exact processes involved are unclear.
One mediator implicated in coagulopathy after
injury is Activated Protein C. Immediate post-injury
coagulopathy is likely a combination of effects caused by
large volume tissue trauma and hypoperfusion.
Several other historic factors are acknowledged for
their contribution to coagulopathy after trauma. Hess
and others continue to acknowledge the impact of dilu-
tion of coagulation factors with crystalloid resuscitation
after injury [19]. While acknowledging inadequate clini-
cal data at present, equivalent ratios of FFP, PRBCs and
platelets must be considered for management of coagu-
lopathy after injury. Hypothermia and acidemia are con-
trolled to reduce their impact on enzyme systems [31].
Inflammation is receiving greater attention as a conse-
quence of severe injury. Recent data suggests earlier
activation of the immune system after injury than pre-
viously proposed. Similar to sepsis, cross-talk has been
noted between coagulation and inflammation systems.
Activation of coagulation proteases may induce inap-
propriate inflammatory response through cell surface
receptors and activation of cascades such as Comple-
ment and platelet degranulation [32-34]. Trauma
patients are initially coagulopathic with increased bleed-
ing but may progress to a hypercoagulable state putting
them at increased risk for thrombotic events. This late
thrombotic state bears similarities with coagulopathy of
severe sepsis and depletion of Protein C. Injured and
septic patients share a propensity toward multiple organ
failure and prothrombotic states. A diagram displaying
the interrelated mechanisms contributing to coagulopa-
thy after trauma is presented (Figure 2).
Blood Component Therapy and the “Ratio”
Despite work from multiple groups suggesting that sim-
ple replacement of packed red blood cells was not a suf-
ficient answer to the most severely injured patient,
particularly in the setting of coagulopathy, the concept
of combination blood component replacement remained
outside the mainstream of trauma care for over 20 years
[7,8,3]. In part, this may reflect the difficulty in charac-
terizing coagulopathy after injury due to limitations of
Figure 2 Diagram showing some of mechanisms leading to
coagulopathy in the injured. ACoTS = Acute Coagulopathy of
Trauma-Shock.
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flicts in the Middle East and experience in a multina-
tional group of trauma centers to bring awareness of the
need for multiple blood component therapy in massive
bleeding to the level of general trauma practice.
The 1970s and 1980s saw several groups propose
resuscitation of significant hemorrhage with combina-
tions of blood components. Kashuk and Moore pro-
posed multicomponent blood therapy in patients with
significant vascular injury [3]. In a study of patients with
major abdominal vascular injury, Kashuk and coworkers
noted frequent deviation from a standard ratio of 4:1 or
5:1 for units of packed red blood cells to units of Fresh
Frozen Plasma. The ratio was 8:1 in nonsurvivors and
9:1 where overt coagulopathy was noted. Fifty-one per-
cent of patients in this series were coagulopathic after
vascular control was obtained. Using multivariate analy-
sis, Ciavarella and coworkers from the Puget Sound
Blood Center and Harborview Medical Center proposed
aggressive supplementation of platelets in the setting of
massive transfusion. These investigators noted that pla-
telet counts below 50 × 10
9 per liter correlated highly
with microvascular bleeding in trauma and surgery
patients. Fibrinogen repletion was also emphasized.
Other guides to resuscitation included fibrinogen level,
prothrombin time and partial thromboplastin time. Sup-
plemental Fresh Frozen Plasma or cryoprecipitate was
recommended for low fibrinogen levels [8]. Lucas and
Ledgerwood, summarizing extensive preclinical and clin-
ical studies, suggested administration of Fresh Frozen
Plasma after 6 units of packed red blood cells had been
infused. Additional Fresh Frozen Plasma was recom-
mended for every five additional packed red blood cell
transfusions. Monitoring included platelet count, PT
and PTT after each 5 units of packed red blood cells are
administered. Platelet transfusion is generally unneces-
sary unless the platelet count falls below 50,000 [7].
Despite this early work, blood loss continues to be the
major cause of early death after injury accounting for
50% of deaths occurring during the initial 48 hours after
hospitalization. Bleeding remains a common cause of
preventable deaths after injury [35-37]. Many centers
are beginning to establish protocols for massive transfu-
sion practice but criteria and compliance continues to
vary. Trauma centers are examining approaches to com-
prehensive hemostatic resuscitation as a replacement
strategy for earlier approaches based on rapid, early
infusion of crystalloids and PRBCs alone [17-20].
Rhee and coworkers, using the massive database of the
Los Angeles County Level I Trauma Center, examined
transfusion practices in 25,000 patients [38]. Approxi-
mately 16% of these patients received a blood transfu-
sion. Massive transfusion (≥10 units of PRBCs per day)
occurred in 11.4% of transfused patients. After excluding
head-injured patients, these authors studied approxi-
mately 400 individuals. A trend toward increasing FFP
use was noted during the six years of data which was
reviewed (January 2000 to December 2005). Logistic
regression identified the ratio of FFP to PRBC use as an
independent predictor of survival. With a higher the
ratio of FFP:PRBC, a greater probability of survival was
noted. The optimal ratio in this analysis was an FFP:
PRBC ratio of 1:3 or less. Rhee and coworkers provide a
large retrospective dataset demonstrating that earlier
more aggressive plasma replacement can be associated
with improved outcomes after bleeding requiring mas-
sive transfusion. Ratios derived in this massive retro-
spective data review support the observations of
Hirshberg, Mattox and coworkers [11]. Like the data
presented by Kashuk and coworkers in another widely
cited report, this retrospective dataset suggests improved
clinical outcome with increased administration of FFP
[39] (Figure 3).
Another view of damage control hematology comes
from Vanderbilt University Medical Center in Nashville,
Tennessee. This group implemented a Trauma Exsan-
guination Protocol involving acute administration of 10
units PRBC with 4 units FFP and 2 units platelets. In an
18 month period, 90 patients received this resuscitation
and were compared to a historic set of controls. The
group of patients receiving the Trauma Exsanguination
Protocol as described by these investigators had lower
mortality, much higher blood product use in initial
operative procedures and higher use of products in the
initial 24 hours though overall blood product consump-
tion during hospitalization was decreased [40].
The strongest multicenter civilian data examining the
impact of plasma and platelet administration along with
red blood cells on outcome in massive transfusion
comes from Holcomb and coworkers [41]. These inves-
tigators report over 450 patients obtained from 16 adult
Figure 3 Mortality Decrease with Higher FFP:PRBC Ratios.
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59%. Patients were gravely ill as reflected by an admis-
sion base deficit of -11.7, pH 7.2, Glasgow Coma Score
of 9 and a mean Injury Severity Score of 32. Examina-
tion of multicenter data reflects an improvement in out-
come as the ratio of Fresh Frozen Plasma to packed red
blood cells administered approaches 1. Fresh Frozen
Plasma, however, is not the sole solution to improved
coagulation response in acute injury. These workers also
examined the relationship of aggressive plasma and pla-
telet administration in these patients. Optimal outcome
in this massive transfusion group was obtained with
aggressive platelet as well as plasma administration.
Worst outcomes were seen when aggressive administra-
tion of plasma and platelets did not take place. Where
either FFP or platelets were given in higher proportion
in relationship to packed red cells intermediate results
were obtained. Not surprisingly, the cause of death
which was favorably affected was truncal hemorrhage.
Examination of the Kaplan-Meier curves provided by
these workers demonstrates that the impact of early
blood product administration on mortality is seen in
improved outcomes immediately after injury (Figure 4).
A summary statement comes from Holcomb and a
combination of military and civilian investigators
[18,19]. These workers identify a patient group at high
risk for coagulopathy and resuscitation failure due to
hypothermia, acidosis, hypoperfusion, inflammation and
volume of tissue injury. In the paradigm proposed by
these writers, resuscitation begins with prehospital lim-
itation of blood pressure at approximately 90 mmHg
preventing renewed bleeding from recently clotted ves-
sels. Intravascular volume resuscitation is accomplished
using thawed plasma in a 1:1 or 1:2 ratio with PRBCs.
Acidosis is managed by use of THAM and volume load-
ing with blood components as hemostasis is obtained.
These workers utilize rFVIIa “occasionally” along with
early units of red cells. A massive transfusion protocol
for these investigators included delivery of packs of 6
units of plasma, 6 units of PRBC, 6 units of platelets
and 10 units of cryoprecipitate in stored individual cool-
ers. These coolers are continued until notification
comes from the trauma team. Even in causalities requir-
ing resuscitation with 10-40 units of blood products,
Holcomb and coworkers found that as little as 5-8 liters
of crystalloid are utilized during the first 24 hours repre-
senting a decrease of at least 50% compared to standard
practice. The lack of intraoperative coagulopathic bleed-
ing allows surgeons to focus on surgical hemorrhage.
T h eg o a li sa r r i v a lo ft h ep a t i e n ti nI C Ui naw a r m ,
euvolemic and nonacidotic state. INR approaches nor-
mal and edema is minimized. Subjectively, patients trea-
ted in this way are more easily ventilated and easier to
extubate than patients with a similar blood loss treated
with standard crystalloid resuscitation and smaller
amounts of blood products. Clearly, these clinical obser-
vations warrant development of hypothesis-driven
research. Holcomb and others suggest that massive
transfusion will be required in 6-7% of military practice
and 1-2% of civilian trauma patients.
An intriguing evaluation of the relationship of blood
product administration to mortality comes from the
Alabama School of Medicine in Birmingham [42].
Again, patients requiring massive transfusion defined as
>10 units PRBCs within 24 hours were studied. One
hundred thirty-four individuals met this definition
between 2005 and 2007. This study, however, defined
FFP:PRBC ratios in two ways; first, as a fixed value at 24
hours and then as a time varying covariate. High ratio
was defined as >1:2 with low ratio as <1:2 units of FFP:
PRBCs. Using 24 hour mortality comparison, patients
with a high ratio of FFP:PRBCs administered had a sig-
nificant improvement in outcome. As is the case in
other studies of massive transfusion, mortality occurred
early in hospital course.
In a telling second analysis, the Alabama investigators
examined temporal mortality among low and high ratio
patient groups [42]. During early time intervals, most
deaths occurred in the group receiving a low ratio for
that interval while during the later time intervals more
Figure 4 30-day survival using Kaplan-Meier curves comparing
patients receiving high ratios of fresh frozen plasma (FFP) and
platelets to PRBCs versus patients receiving low ratios of either
FFP or platelets. Patients with best outcomes had high ratios of
both FFP and platelets to PRBCs while worst outcomes came with
low ratios of both FFP and platelets to PRBCs. Where one
component, either FFP or platelets was low, intermediate outcomes
were obtained.
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ratio. The pattern of mortality in this data includes the
potential for survival bias as the majority of deaths
occurred when most patients resided in the low ratio
group, before the accumulation of patients in the high
ratio group. These investigators then performed Cox
regression modeling with FFP:PRBC ratio as a time
dependent coordinate. In this assessment, the survival
advantage associated with the high ratio group as
demonstrated previously disappeared. Adjustment for
platelet, cryoprecipitate and rFVIIa administration did
not change this result. Because many deaths, those asso-
ciated with hemorrhage, occurred early in the hospital
course, many patients in these time intervals were in the
low ratio group (low FFP use) rather than the high ratio
group. Survival bias was introduced as patients in the
low ratio group died early which fixed them at a low
FFP:PRBC ratio and prevented them from transitioning
to the high ratio group. These observations are also
reflected in a paper from the Stanford group by Riskin
and coworkers. Riskin and others identified improved
outcomes with rapid administration of blood products
to appropriate patients even if equivalent amounts of
FFP and PRBCs were employed [43]. This important
analysis of retrospective data reinforces the need for
carefully orchestrated prospective studies.
Complications of Massive Transfusion
There are many clinical issues beyond component
“ratios” for the injured patient.
TRALI
While summary data suggests that increased use of
plasma and platelets may improve outcome in the set-
ting of massive transfusion, use of these additional com-
ponents should be done thoughtfully [44-47]. A growing
body of work describing Transfusion-Related Acute
Lung Injury (TRALI) identifies early and late respiratory
failure secondary to this problem as the major complica-
tion of transfusion. The likelihood of TRALI increases
with plasma-based products;t h u s ,F r e s hF r o z e nP l a s m a
and platelets may place patients at increased risk. At
present, we can only provide supportive care for the
patient with TRALI, though use of fresh products may
reduce the risk of late TRALI which appears to be a sto-
rage lesion. We must also be aware that giving packed
red cells, platelets and plasma in a 1:1:1 ratio does not
replace fresh whole blood which may be the optimal
blood product for resuscitation. In a recent review, Sih-
ler and Napolitano point out that administration of
stored components in a 1:1:1 ratio provides reduced
amounts of red cells, clotting factors and platelets rela-
tive to fresh whole blood. FFP, however, may provide
secondary benefit as a fibrinogen source [45,47,48].
Transfusion Risks May Be Increased With “Old” Blood
Modern blood banking is based on component therapy.
Blood components undergo changes during storage
which may affect the recipient including release of
bioactive agents with immune consequences. Generation
of inflammatory mediators is related to duration of unit
storage. Small datasets note an increased risk of multiple
organ failure where the age of units of transfused blood
is increased. Thus, fresh blood may be the most appro-
priate initial resuscitation product for trauma patients
requiring transfusion [49-52].
Other age-related changes of stored blood have been
identified. For example, red cell deformability is reduced
not only after injury but in stored blood as the duration
of storage increases. Supernatants from stored red blood
cells have been documented to prime inflammatory cells
in vitro and induce expression of adhesion molecules in
neutrophils and proinflammatory cytokines. Among
proinflammatory cytokines identified are IL-6, IL-8 and
TNF-a. Finally, with increased length of red blood cell
storage, free hemoglobin concentrations in red cell pro-
ducts are increased. Free hemoglobin in units of stored
red blood cells can bind nitric oxide and cause vasocon-
striction. Local vascular effects related to the vasocon-
strictive properties of stored red blood cells may limit
off-loading of oxygen to tissues, the principle rationale
for transfusion [49,50].
What is the Effect of Giving Uncross-matched Blood?
Many centers initiate blood product resuscitation with
uncross-matched blood. Lynn and coworkers have
examined their clinical experience with administration
of uncross-matched type-O red blood cells [53]. This
product is given at the discretion of attending physicians
to patients with active hemorrhagic shock and need for
immediate transfusion before the availability of cross-
matched blood. Frequently, the decision for giving
uncross-matched type-O PRBCs is a subjective assess-
ment based on vital signs, physical examination and
experience. In a review of over 800 patients from a five
year period, approximately 3,000 units of uncross-
matched type-O blood were given. The mean Injury
Severity Score in the patients receiving this blood was
32. The univariate analysis based on amount of uncross-
matched type-O blood demonstrated a linear correlation
between the number of units given and the probability
of death. Obviously, quantity of uncross-matched type-
O blood given is also a surrogate for depth of shock,
rate of hemorrhage and is a marker for mortality due to
injury. These observations were confirmed by Inaba and
coworkers who examined use of over 5,000 uncross-
matched units over six years. Administration of uncross-
matched blood was indicative of the need for massive
transfusion and higher mortality [54].
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Little is written about the criteria for activation of a
massive transfusion protocol. In our trauma center, we
use the classification of shock, secondary to hemorrhage,
promoted by the American College of Surgeons and the
Advanced Trauma Life Support (ATLS) program [55].
Patients presenting with persistent hypotension in con-
junction with other signs of Class III shock are candi-
dates for administration of our massive transfusion
protocol. Repeated determination of vital signs and the
appropriate clinical setting is necessary to trigger the
massive transfusion protocol. Despite using this time-
honored set of criteria, many patients who do not
require massive transfusion may be started on this pro-
tocol. We clearly need better criteria to determine initia-
tion of a massive transfusion protocol. As noted above,
historical data and recent reports from the military, sug-
gest that in the military setting, 6-7%% of patients will
require massive transfusion, and in the civilian setting,
only 1-2% of patients will require massive transfusion
[18].
A recent analysis from the German Trauma Registry
examined parameters available within the first 10 min-
utes after hospital admission as predictors of the need
for massive transfusion [56]. Massive transfusion was
defined in this analysis as administration of at least 10
units of PRBCs during the initial phase of therapy. The
result was a simple scoring system called TASH
(Trauma-Associated Severe Hemorrhage) using hemo-
globin (2-8 points), base excess (1-4 points), systolic
blood pressure (1-4 points), heart rate (2 points), free
fluid on abdominal ultrasound (3 points), open and/or
dislocated fractures of extremities (3 points), pelvic frac-
ture with blood loss (6 points) and male gender (1
point). A score of 15 points in the TASH Scale predicts
a5 0 %r i s ko fm a s s i v et r a n s f u s i o n .L y n ns u g g e s t st h a t
similar indicators emerged in a review of the Miami
Trauma Registry [53].
Cotton and the group at Vanderbilt in the United
States propose a similar predictive score reflecting the
need for massive transfusion in trauma [57]. These
authors identify four dichotomous components available
at the bedside of injured patients early in evaluation.
The presence of any one component contributes one
point to the total score for a possible range of scores
from 0 to 4. Parameters include penetrating mechanism
(0 = no, 1 = yes); Emergency Department systolic blood
pressure of 90 mmHg or less (0 = no, 1 = yes); Emer-
gency Department heart rate of 120 beats/min or greater
(0 = no, 1 = yes); and positive abdominal sonogram (0 =
no, 1 = yes). When all of these factors are present, the
Nashville group suggests that the likelihood of massive
transfusion is very high (Figure 5). Examination of con-
tribution from individual components to the ABC
(Assessment of Blood Consumption) Score of these
investigators reveals that each contributes in roughly
equal proportion (Figure 6). In a second multicenter
study, Cotton and coworkers validated the ABC Score
with data obtained from Parkland Hospital in Dallas, the
Johns Hopkins Institutions in Baltimore and a dataset
for Vanderbilt University. The predictive value of the
ABC Score was consistent across the three trauma cen-
ters examined. In fact, the negative predictive value was
97% across this trial. From this data, the authors argue
that less than 5% of patients who will require massive
transfusion will be missed using the ABC Score [58].
In another recent study, Cotton and coworkers evalu-
ated the ability of uncross-matched blood transfusion in
the Emergency Department to predict early (<6 hours)
massive transfusion of red blood cells and blood compo-
nents. Massive transfusion was defined as the need for
10 units or more of packed red blood cells in the first
ABC Score
Figure 5 Rate of Massive Transfusion by ABC Score.
ABC Score
Figure 6 Individual contribution of each component of ABC
Score to the likelihood of massive transfusion.
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defined as six units or more of plasma in the first six
hours. Early massive transfusion of platelets was defined
as two or more apheresis platelet transfusions in the
first six hours. These authors studied 485 patients who
received Emergency Department transfusions and 956
patients who did not receive Emergency Department
transfusions after trauma. Patients receiving uncross-
matched red blood cells in the Emergency Department
were more than three times more likely to receive early
massive transfusion of red blood cells. These authors
recommend considering Emergency Department trans-
fusion of uncross-matched red blood cells as a trigger
for activation of an institution’s massive transfusion pro-
tocol [59].
What is a Massive Transfusion Protocol?
Massive transfusion is most commonly defined as
administration of ten units of packed red blood cells in
the first 24 hours after admission to hospital. Generally,
this does not include emergency department uncross-
matched products. Cotton, Holcomb and coworkers
define massive transfusion of plasma as the administra-
tion of six units or more in the first 24 hours after
admission. Massive transfusion of platelets is defined as
the transfusion of two or more apheresis units in the
first 24 hours after admission. These workers distinguish
between “early” massive transfusion and massive trans-
fusion in recent writings. Early massive transfusion of
r e db l o o dc e l l si sd e f i n e da st ransfusion of ten units or
more of packed red blood cells in the first six hours
after admission. Early massive transfusion of plasma is
defined as administration of six units of plasma or more
in the first six hours after admission. Early massive
transfusion of platelets is defined as transfusion of two
or more apheresis units in the first six hours after
admission. In defining massive transfusion and early
massive transfusion in this way, the authors address the
time bias which may be associated with the pattern of
blood product administration and attempt to distinguish
between the patient requiring therapy for early emergent
bleeding as opposed as to the patient requiring ongoing
stabilization with blood product administration [59].
Role of Recombinant Factor VIIa
Recombinant FVIIa (rFVIIa) was introduced in the
1980s as a hemostatic agent [60]. Recombinant FVIIa is
thought to act locally at the site of tissue injury and vas-
cular wall disruption by injury with presentation of Tis-
sue Factor and production of Thrombin sufficient to
activate platelets. The activated platelet surface can then
form a template on which rFVIIa can directly or indir-
ectly mediate further coagulation resulting in additional
thrombin generation and ultimately fibrinogen conver-
sion to fibrin. Clot formation is stabilized by inhibition
of fibrinolysis due to rFVIIa-mediated activation of
Thrombin Activatable Fibrinolysis Inhibitor. Initially,
rFVIIa was used in patients with congenital or acquired
hemophilia and inhibiting antibodies toward factor VIII
or IX and it has been licensed in the United States and
other parts of the world for this purpose. There is sig-
nificant off-label use of rFVIIa in surgical applications
including uncontrolled bleeding in the operating room
or following injury.
Other recent investigations suggest that rFVIIa acts by
binding activated platelets and activating Factor Xa on
platelet surface independent of its usual co-factor, Tis-
sue Factor. The activation of Factor X (FX) on the plate-
let surface would normally be via the FIXa-FVIIIa
complex which is deficient in hemophilia. Factor Xa
produces a “burst” of thrombin generation required for
effective clot formation. At high doses, rFVIIa can par-
tially restore platelet surface FX activation and thrombin
generation [61,62].
Until recently, much of the literature associated with
rFVIIa comes from case reports or uncontrolled series.
In fact, a literature review published in 2005 by Levi and
coworkers identified publications with rFVIIa noted
until July, 2004. The majority of publications were case
reports or case series. Twenty-eight clinical trials repre-
sented 6% of publications. Eleven of the clinical trials
addressed the needs of hemophiliacs, three trials
reflected patients with other coagulation defects while
seven trials were devoted to patients with liver disease.
Only one study at the time of this review was conducted
in surgical patients. Thus, much of the work of the
trauma community with rFVIIa is recent and the num-
ber of studies is small [63,64].
Physiologic limits for the use of rFVIIa in the setting
of injury are being identified [65]. Meng and coworkers
examined the effectiveness of high dose rFVIIa in
hypothermic and acidotic patients. This group studied
blood collected from healthy, consenting adult volun-
teers. For temperature studies, blood reactions with
rFVIIa were kept at 24°C, 33°C and 37°C. For pH stu-
dies, the pH of the reaction was adjusted by solutions of
saline buffered to obtain the desired pH. In tempera-
tures studies, rFVIIa activity on phospholipids and plate-
lets was not reduced significantly at the 33°C compared
t o3 7 ° C .I na l l ,t h ea c t i v i t yo fr F V I I aa n dT i s s u eF a c t o r
was reduced by approximately 20% at 33°C in compari-
son to 37°C. However, a physiologic pH decrease from
7.4 to 7.0 reduced the activity of rFVIIa with Tissue Fac-
tor by over 60%. These observations are consistent with
clinical data, reviewed below, suggesting reduced efficacy
of rFVIIa in the setting of acidosis.
The largest clinical data set with regard to manage-
ment of trauma comes from Boffard and the NovoSeven
Trauma Study Group [66,67]. These investigators, in a
Dries Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine 2010, 18:63
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whom 143 patients with blunt trauma and 134 patients
with penetrating trauma were eligible for analysis.
Examination of the primary endpoint, red blood cell
transfusion requirements during the initial 48 hour
observation period after the initial dose of study drug,
reveals that administration of rFVIIa in the setting of
blunt trauma significantly reduced 48 hour red blood
cell requirements by approximately 2.6 units. The need
for massive transfusion was reduced from 20 of 61
patients in the placebo group to 8 of 56 patients in the
group receiving rFVIIa. In patients with penetrating
trauma, no significant effect of rFVIIa was observed
with respect to 48 hour red blood cell transfusion
requirements with an aggregate red blood cell reduction
of approximately one unit over the study course. The
need for massive transfusion in penetrating trauma was
reduced from 10 of 54 patients in the placebo group to
4 of 58 patients with rFVIIa. No difference between
treatment groups was observed in either blunt or pene-
trating trauma patient populations with respect to
administration of FFP, platelets or cryoprecipitate.
Despite the reduced need for massive transfusion, there
was no difference in mortality in either the blunt or
penetrating trauma groups.
There are three additional multicenter trials reporting
use of rFVIIa in injured patients [68-70]. Raobaikady and
others examined blood product use in 48 patients treated
for pelvic fractures. The rFVIIa dose employed was 90
μg/kg and the primary outcome examined was periopera-
tive blood loss during reconstruction. No difference was
noted in comparison to patients receiving placebo. In the
recently reported CONTROL Trial, Hauser and cowor-
kers, in a randomized prospective format, studied 573
patients [69]. The majority of these individuals sustained
blunt trauma. Protocol administration for factor VII and
initial trauma care were carefully employed. In patients
with both penetrating and blunt trauma, rFVIIa reduced
blood product use but did not affect mortality compared
with placebo. Thrombotic events were similar across
study groups. This trial was stopped early because of lack
of efficacy for rFVIIa demonstrated on interim statistical
analysis. The largest clinical experience with rFVIIa
comes from the United States military [70]. Wade and
others recently reviewed experience with over 2,000 sol-
diers. A subset of this group, 271 patients, was matched
by epidemiologic criteria to injured soldiers who did not
receive rFVIIa. Fifty-one percent of patients in each
group received massive transfusion. There was no differ-
ence in complications or mortality with administration of
rFVIIa (Table 1).
The largest reported single center North American
experience with rFVIIa comes from the Shock Trauma
Institute at the University of Maryland [71]. In this
retrospective study, experience with 81 coagulopathic
trauma patients treated with rFVIIa during the years
2001 to 2003 is compared with controls matched from
the Trauma Registry during a comparable period. A
number of causes for coagulopathy were noted. The lar-
gest group of patients (46 patients), suffered acute trau-
matic hemorrhage. Traumatic brain injury (20 patients),
warfarin use (9 patients) and 6 patients with various
hematologic defects including 2 individuals with FVII
deficiency were included in this review. Coagulopathy
was reversed, based on clinical response in 61 of 81
cases. Significant reduction in prothrombin time was
seen in patients receiving rFVIIa. Overall mortality in
the patients receiving rFVIIa was 42% versus 43% in a
group of patients identified as coagulopathic with com-
parable injuries and lactate levels identified from the
Trauma Registry. In comparing patients who appeared
to be responders to non-responders to rFVIIa, the
Maryland group noted poorer outcomes in acidotic
patients consistent with previous preclinical work. These
authors did note a small number of severely acidotic
patients who did survive with administration of rFVIIa.
Thus, simple acidosis may warrant reconsideration if
use of rFVIIa is otherwise appropriate. The only throm-
botic complications observed in this series, segmental
bowel necrosis in 3 patients with mesenteric injury after
rFVIIa therapy, was also seen in 2 individuals who did
not receive rFVIIa.
One additional recent trial in hemorrhagic stroke is
worthy of comment. Eight hundred and forty-one
patients with intracerebral hemorrhage were randomized
to placebo, low dose or high dose rFVIIa within 4 hours
of onset of stroke. Endpoints studied were important;
disability and death. Low dose rFVIIa was 20 μg/kg
body weight and high dose rFVIIa was 80 μg/kg body
weight. While scheduled follow-up CT scans demon-
strated reduced volume of hemorrhage in patients
receiving rFVIIa, no difference in functional outcome or
mortality was identified. Serious thromboembolic events
were similar in all three groups. Arterial adverse events
were more frequent in the high dose rFVIIa group than
in placebo (9% versus 4%, p = 0.04). Adverse events
were closely followed. The frequency of elevated tropo-
nin I values was 15%, 13% and 22% and the frequency
of ST elevation myocardial infarction was 1.5%, 0.4%
and 2.0% in the placebo group and the groups receiving
20 μg and 80 μg of rFVIIa per kilogram respectively. CT
evidence of acute cerebral infarction was identified in
2.2%, 3.3% and 4.7% of patients in the placebo group
and the groups receiving 20 μga n d8 0μgo fr F V I I ap e r
kilogram respectively. Age was identified as a risk factor
for thromboembolic events in a post hoc analysis. rFVIIa
is cost effective but has not changed outcomes in trau-
matic brain injury in a more recent trial [72].
Dries Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine 2010, 18:63
http://www.sjtrem.com/content/18/1/63
Page 10 of 17Most concerning in recent discussion regarding the
u s eo fr F V I I ai nt h es e t t i n go fi n j u r yi sap o t e n t i a lr o l e
for this material in magnifying early traumatic coagulo-
pathy. Administration of rFVIIa in supraphysiologic
doses may increase combined activity of Thrombin and
Thrombomodulin. Within the coagulation cascade,
Thrombomodulin from endothelium complexes with
Thrombin in association with activation of Protein C
and its cofactor Protein S. Through consumption of
Plasminogen Activator Inhibitor I, fibrinolysis is
increased and Tissue Plasminogen Activator is also
released by endothelium in shock states contributing to
fibrinolysis (discussed above). In addition to effects just
listed, increased binding of Thrombin to Thrombomo-
dulin reduces conversion of Fibrinogen to Fibrin and
platelet activation. If, therefore, in the setting of hypo-
perfusion, administration of rFVIIa increases Thrombin
production, additional activation of Protein C (with coa-
gulopathy) may occur rather than generation of Fibrin.
Administration of rFVIIa in the setting of hypoperfusion
may contribute to rather than control coagulopathy
[1,60].
Two recent metaanalyses also suggest a cautious
approach [73,74]. Hsia and others conclude that the use
of rFVIIa may reduce the need for blood transfusion
and possibly reduce mortality [73]. The dose of rFVIIa
should be limited to 90 μg/kg and an increased risk of
arterial thrombosis may exist. A more pessimistic view
comes from Hardy and two coauthors in a recent review
from the Annals of Thoracic Surgery [74]. These workers
conclude that generalized use of rFVIIa to prevent or
control bleeding in nonhemophiliac patients cannot be
recommended [66,74].
Newer Products
Prothrombin Complex Concentrate
Currently, Fresh Frozen Plasma (FFP) is the standard
choice to correct coagulopathy after major injury. Draw-
backs associated with FFP such as the need for thawing
and the requirement for ABO compatibility may be lim-
ited by holding thawed plasma or administering Type
AB or Type A plasma in emergencies. These resources
m a yo n l yb ea v a i l a b l ei nm a j o rt r a u m ac e n t e r s .Am o r e
readily available and concentrated coagulation factor
replacement such as Prothrombin Complex Concentrate
(PCC) could provide advantages in emergent situations
[75-77]. In addition to factor VII, PCC contains coagula-
tion factors II, IX and X and the anticoagulation pro-
teins C and S. PCC in combination with fibrinogen has
been shown to enhance coagulation and final clot
strength in a porcine model of dilutional coagulopathy
[78]. More recent work using controlled splenic injury
and hemodilution demonstrates more rapid hemostasis
and augmented thrombin generation in comparison to
rFVIIa. Notably, time to splenic hemostasis was not sig-
nificantly reduced by rFVIIa in comparison to placebo
[79].
Tranexamic Acid
Part of the response to surgery and trauma is clot
breakdown (fibrinolysis), which may become pathologi-
cal in the setting of injury. Antifibrinolytic agents reduce
blood loss in patients with both normal and exaggerated
fibrinolytic response to surgery and do so without
apparent increase in postoperative complications
[80-82].
Tranexamic acid is a synthetic derivative of the ami-
noacid lysine which inhibits fibrinolysis by blocking the
lysine binding sites on plasminogen. Fifty-three studies
including 3,836 participants have involved tranexamic
acid in patients undergoing elective surgery. Tranexamic
acid reduced the need for blood transfusion by a third
in these patients with no significant reduction in mortal-
ity. Tranexamic acid was recently investigated as a
means to reduce blood product utilization and mortality
in trauma patients [83,29,36,84].
In a massive randomized, control trial spanning 40
countries, over 20,000 adult trauma patients with or risk
of significant bleeding were randomly assigned within
eight hours of injury to either tranexamic acid (loading
dose 1 gram over 10 minutes and then infusion of 1
gram over 8 hours) or matching placebo [84]. Randomi-
zation was balanced by center and participants and
Table 1 Summary of Important Trials Published*
Author and Year Patient Group rFVIIa Dosing Primary Endpoint Outcomes
Boffard; [67] J Trauma 2005; 59:8-18 Penetrating and blunt
trauma (301)
200+100+100
μg/kg
RBC units first 24 hours Reduction in RBCs (blunt)
Raobaikady; [68] Br J Anaesth 2005;
94:586-591
Pelvic fractures (48) 90 μg/kg Perioperative blood
loss
No difference
Hauser; [69] J Trauma 2010; 69:489-
500
Blunt and penetrating
trauma (573)
200+100+100
μg/kg
Mortality, blood
product use
No mortality difference, Less
product use
Wade; [70] J Trauma 2010; 69:353-
359**
Military trauma (2,050) Varied Complications,
mortality
No difference
*Modified from Ann Emerg Med 2009; 54:737-744.
**Large retrospective case control analysis.
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primary outcome was death in hospital within four
weeks of injury described with complications including
bleeding, vascular occlusion, multiorgan failure, trau-
matic brain injury and others. All cause mortality was
significantly reduced with tranexamic acid (14.5%) in
comparison to placebo (16.0%). The risk of death speci-
fic to bleeding was also significantly reduced (4.9% with
tranexamic acid vs 5.7% with placebo). This is by far the
largest outcome study related to bleeding in the setting
of injury. The use of tranexamic acid is supported by
this large dataset. Remarkably, there were no adverse
events regarded as serious, unexpected, or suspected to
be related to the study treatment. Even more important,
the results of this trial were not dependent on the
results of laboratory tests. Study admission was based
on clinical criteria. One can speculate that administra-
tion of this material guided by appropriate laboratory
testing might lead to even stronger support for its use.
The authors freely admit that this trial provides lim-
ited insight into the mechanism by which tranexamic
acid reduces the risk of death in bleeding patients after
injury. Previous workers have demonstrated, however,
that hyperfibrinolysis is a frequent feature of coagulopa-
thy after injury and raise the possibility that antifibrino-
lytic agents such as tranexamic acid might operate via
this mechanism. Unfortunately, this trial did not mea-
sure fibrinolytic activity. Finally, the authors note that
additional work is required to determine if tranexamic
acid is beneficial in the setting of traumatic brain injury.
Monitoring of Coagulopathy
Up to 25% of multiple trauma patients suffer from coa-
gulopathy. Coagulopathy may be associated with hemo-
dilution, transfusion of blood products, hypothermia,
acidosis and shock. As Fresh Frozen Plasma, coagulation
factors and other pharmacologic therapies are adminis-
tered, it is of great value to monitor the effects of these
interventions on coagulation. The current standard of
care for coagulation assessment is a series of tests
including prothrombin time expressed as international
normalized ratio (INR), activated partial thromboplastin
time (APTT), thrombin time (TT) and platelet counts.
This monitoring is often flawed because of differences
between laboratory conditions in the clinical environ-
ment together with significant intervals between drawing
of blood and obtaining results which may render these
tests useless [85,86].
One approach to this problem would be to improve
point of care monitoring of coagulation using the tech-
nique of thrombelastography (TEG). TEG offers the
advantage of providing a real-time graphic representa-
tion of clot formation and whole blood. Unlike standard
laboratory tests, TEG offe r sa n a l y s i so ft h ew h o l e
coagulation cascade permitting identification of depleted
components and directed therapy to correct coagulopa-
thy. The procedure involves placing a small volume of
blood in an oscillating cup at 37°C or at patient tem-
perature. As the blood in the cup clots, the motion of
the cup as rotated is transmitted to a pin dipped in the
blood. TEG has been used in preliminary studies to
evaluate changes in coagulation in injured patients
[85-88].
Carroll and coworkers evaluated a TEG system and
platelet mapping, which can also be performed using a
TEG technology, and correlated these values with trans-
fusion and fatality in a series of trauma patients. Initial
blood samples in this study were obtained at accident
scenes and in the Emergency Department. Overall, little
difference was seen in TEG parameters between the
accident scene and Emergency Department. Standard
TEG parameters and the platelet mapping assay
employed did not correlate with the need for transfusion
except in patients where poor platelet function was
identified. However, abnormality in TEG parameters
and platelet mapping studies were strongly correlated
with mortality. In this respect, TEG and platelet map-
ping parameters were more sensitive than standard clot-
ting tests such as PT, aPTT and platelet count [89].
Thrombelastography (TEG) may also facilitate detec-
tion of hypercoagulable states. In an ICU study of
burned and traumatized patients, Park and coworkers
found a significant number of non-bleeding injured
patients developed a hypercoagulable state within the
initial days after injury. In comparison of TEG to PT
and aPTT, TEG demonstrated increased coagulation
while PT and aPTT did not. Despite aggressive throm-
boprophylaxis in patients followed during this study, 3
of 58 patients suffered pulmonary emboli [90].
As discussed in an excellent review by Kashuk, Moore
and others, TEG was first described in 1948 [1,91]. It
assesses clot strength from the time of initial fibrin for-
mation to clot retraction ending in fibrinolysis. TEG is
t h eo n l ys i n g l et e s tp r o v i d i n gi n f o r m a t i o no nt h eb a l -
ance between the opposing components of coagulation,
thrombosis and lysis while the battery of traditional coa-
gulation tests, which include bleeding time, PT, aPTT,
thrombin time, fibrinogen levels, factor assays, platelet
counts and functional assays are based on isolated, static
data points [92,93]. TEG examines interaction of the
entire clotting cascade and platelet function in whole
blood. PT measures only the extrinsic clotting system
while aPTT examines an enzymatic reaction in the
intrinsic clotting cascade. Hypothermia, a common com-
plication of injury also affects the coagulation process
and leads to functional abnormalities. Platelet dysfunc-
tion is influenced by thrombin and fibrinogen concen-
trations and can be affected by hypothermia, acidosis
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with TEG comes from Europe. Some European centers
use the ROTEM device which differs from classic TEG
in that the blood specimen is stationary while the pin is
rotated instead of the cup. Like TEG, ROTEM has been
useful in providing global evaluation of the coagulation
process including fibrinolysis [94].
A variant of TEG reported by the Denver group is
rapid Thrombelastography (rTEG). rTEG differs from
conventional TEG in that Tissue Factor is added to the
whole blood specimen allowing a more rapid coagula-
tion reaction and subsequent evaluation. A recent Eur-
opean report also suggests that rTEG is useful in
evaluation of patients after injury [1,88,23].
The most sophisticated North American program of
blood component resuscitation guided by rTEG has
been developed by investigators in Denver [1]. The Den-
ver group uses component infusion therapy based on
rTEG findings. They anticipate use of FFP to provide a
final ratio of 1:2 to 1:3 units of FFP to Packed Red
Blood Cells and propose that goal-directed therapy
using rTEG facilitates stepwise correction of coagulation
abnormalities by comparative assessment of serial rTEG
tracings (Figure 7). A particular benefit of this approach
is identification of fibrinolysis which may be treated
with epsilonaminocaproic acid. Hyperfibrinolysis may
also be identified with ROTEM technology. The Denver
protocol is depicted based on a series of rTEG measures
[94,88,23].
Two recent European consensus statements reflect on
the dilemma of monitoring blood component therapy in
the setting of resuscitation. Gaarder and coworkers in
the Scandinavian Guidelines - “The Massively Bleed-
ing Patient” suggest a relationship between administra-
tion of FFP and red cell products given the dose
adjustment by laboratory measurement of fibrinogen,
coagulation parameters and by thrombelastography [95].
In the setting of uncontrolled bleeding, recommended
administration of plasma is in a 1:1 ratio with red cell
products with guidance by the parameters described
above. These authors further acknowledge limitation of
conventional coagulation assays to describe the dynamic
bleeding condition of injured patients [96,97]. TEG is,
therefore, recommended by the group as a whole blood
analysis providing quantitative information regarding
hemostasis and changes occurring in coagulation
response during product infusion. These writers hold
TEG superior with regarding to identification of clini-
cally relevant coagulopathy and as a predictor of the
need for product administration in trauma patients [87].
A more conservative stance is found in the recent
European Guideline (Management of Bleeding Follow-
ing Major Trauma: An Updated European Guide-
line). Rossaint and the authors of this guideline
recommend routine measure of INR, aPTT, fibrinogen
levels and platelet counts. They also suggest that TEG
be performed to assist in characterizing coagulopathy
and in guiding hemostatic therapy [98].
The updated European guideline notes little evidence
supporting optimal hemostatic monitoring tools in the
setting of bleeding with trauma [98]. INR and aPTT
monitor only the initiation of blood coagulation and
represent a small fraction of thrombin production.
Thus, conventional coagulation screens may be normal
while overall blood coagulation is abnormal. Authors of
the European consensus statement acknowledge TEG as
a means to provide more complete monitoring of blood
coagulation and fibrinolysis. Case series using TEG as
reviewed by these authors have mixed results. Some
authors utilize TEG to guide resuscitation with early
platelet and Fresh Frozen Plasma administration and
s u g g e s ti m p r o v e do u t c o m e s .O t h e rw o r kd e m o n s t r a t e s
poor correlation between TEG and conventional coagu-
lation parameters (however, this may be appropriate).
Another possible approach is more frequent
Figure 7 Denver rTEG Protocol - G is a computer-generated
value reflecting the complete strength of the clot from initial
fibrin burst through fibrinolysis and is calculated from
amplitude which begins at the bifurcation of the tracing. This is
based on a curvilinear relationship: G = (5,000 × amplitude)/(100
minus amplitude). Conceptually, G is the best measure of clot
strength as it reflects the contributions of the enzymatic and
platelet components of hemostasis. Normal coagulation is defined
as G between 5.3 and 12.4 dynes/cm
2.
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tion of trends which may predict coagulation outcomes
after injury [99,85,100].
Conclusion
Our understanding of the coagulopathy of trauma has
changed significantly in recent years. In the setting of
under perfusion and significant volume of tissue injury,
coagulation abnormality may occur before fluid adminis-
tration contrary to historical teaching which emphasizes
hemodilution in the setting of massive crystalloid resusci-
tation. Development of early coagulopathy after trauma is
an independent predictor of poor outcome. Growing
recognition of early coagulopathy after injury has led to
renewed emphasis on early blood product administration
in the injured patient with bleeding [101,102].
While much important work has been done, we have
more questions than answers in this area [103]. A number
of simple observations can be made. Hemorrhage is still a
common factor in the majority of patients sustaining early
mortality after trauma [35]. Early use of blood products
decreases the use of blood [47]. Criteria to identify patients
appropriate for blood product administration are being
developed [56,57]. The most promising of these criteria
are the TASH Score from German investigators and the
ABC Score from Cotton and coworkers. We continue to
investigate the optimal combination of blood component
therapy. In civilian practice, however, a ratio of packed red
cells, Fresh Frozen Plasma and platelets of 1:1:1 is not
equivalent to fresh whole blood, a clinical gold standard
[44,47] (Table 2). Most investigators now agree that ratios
of red blood cell units to plasma units should be no more
than 2:1 to 3:1. Platelets must also be given but the dose
varies with collection technique. An apheresis unit from
one blood bank may be equivalent to several platelet
“packs” from another source. Finally, rapid use of massive
transfusion in appropriate patients is important.
The limitations of static clotting parameters and factor
levels to characterize bleeding are now better recog-
nized. TEG, ROTEM and rTEG offer real-time multifac-
torial evaluation of the clotting response to injury.
Whether these new techniques also improve our ability
to provide hemostatic resuscitation is unclear [102].
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